Gaucher's Disease Market Report 2026

The gaucher’s disease market size has grown steadily in recent years. It will grow from $1.76 billion in 2025 to $1.84 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to approval of enzyme replacement therapies, improved diagnostic blood tests, rare disease research funding, specialist care availability, patient advocacy programs.

The gaucher’s disease market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to development of next-generation therapies, expansion of newborn screening, increased access to rare disease treatments, growth in personalized medicine, improved patient survival. Major trends in the forecast period include rising adoption of enzyme replacement therapy, increased focus on early genetic diagnosis, expansion of substrate reduction therapies, growing awareness of rare genetic disorders, improved long-term disease management.

The increasing prevalence of genetic abnormalities is expected to drive the growth of the Gaucher’s disease market in the coming years. Genetic abnormalities are changes or mutations in the DNA sequence of a person’s genes that can result in altered features, functions, or characteristics. Gaucher’s disease follows an autosomal recessive inheritance pattern, meaning an individual must inherit two copies of the mutated GBA gene - one from each parent - to develop the condition. People with Gaucher’s disease produce insufficient amounts of this enzyme, leading to the accumulation of fatty substances, called lipids, in organs such as the spleen and liver. For example, in 2023, the Cystic Fibrosis Foundation, a US-based non-profit organization, reported that the total population with cystic fibrosis without lung transplant increased from 31,171 in 2022 to 31,752 in 2023. Therefore, the rising prevalence of genetic abnormalities is propelling the Gaucher’s disease market.

Key companies in the Gaucher’s disease market are focusing on developing innovative technologies, such as next-generation sequencing (NGS), to improve patient care. NGS, also called high-throughput sequencing, is a cutting-edge technology that enables rapid and cost-effective sequencing of DNA and RNA molecules. For instance, in February 2023, Eurofins Genomics LLC, a US-based biotechnology company, launched a whole plasmid sequencing service using advanced Gen3 NGS technology. This service delivers same-day results with single-base accuracy of up to 99%, combining the precision and fast turnaround of Sanger sequencing with the comprehensive analysis capabilities of NGS. It accommodates long DNA constructs ranging from 2.5 to 300 kb. With this approach, Eurofins Genomics US provides researchers with a cost-effective, time-efficient solution for long-read sequencing, offering a unique combination of accuracy and speed in genetic analysis.

In May 2025, WuXi Biologics, a China-based contract research, development, and manufacturing organization (CRDMO), partnered with CANbridge Pharmaceuticals, a biopharmaceutical company, to support the development and manufacturing of velaglucerase-beta (Gaurunning), approved by China’s NMPA for Gaucher disease. Through this collaboration, WuXi Biologics leverages its biologics expertise to help CANbridge scale production of this enzyme-replacement therapy, enabling broader access for Gaucher patients. CANbridge Pharmaceuticals, a China-based biotech firm, specializes in developing novel therapies for rare diseases, particularly Gaucher disease.

Major companies operating in the gaucher’s disease market are Pfizer Inc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Sanofi S.A., BioMarin Pharmaceutical Inc., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Protalix BioTherapeutics, AVROBIO Inc., REGENXBIO Inc., Orphazyme A/S, Freeline Therapeutics Holdings plc, CANbridge Life Sciences Ltd, Sangamo Therapeutics Inc, Sigilon Therapeutics Inc, Spur Therapeutics, BioArctic AB, Horizon Therapeutics plc, ERAD Therapeutic, M6P Therapeutics, Lysogene.

North America was the largest region in the Gaucher's disease market in 2025. Europe is expected to be the fastest growing region in the forecast period. The regions covered in the gaucher’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gaucher’s disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gaucher’s disease market by increasing costs of imported enzyme therapies, diagnostic reagents, and infusion-related supplies. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported biologics. These tariffs raise treatment costs by increasing expenses for lifelong enzyme replacement therapy and associated infusion care. However, they support domestic biopharmaceutical manufacturing, encouraging local production of enzyme therapies and improving long-term supply resilience.

The gaucher’s disease market research report is one of a series of new reports that provides gaucher’s disease market statistics, including gaucher’s disease industry global market size, regional shares, competitors with a gaucher’s disease market share, detailed gaucher’s disease market segments, market trends and opportunities, and any further data you may need to thrive in the gaucher’s disease industry. This gaucher’s disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gaucher's disease is a rare genetic disorder that disrupts the metabolism of a specific type of fat called glucocerebroside. The condition results from the accumulation of glucocerebroside within certain cells, particularly in the spleen, liver, bone marrow, and occasionally the brain.

The main types of Gaucher’s disease include Gaucher disease type 1, Gaucher disease type 2, Gaucher disease type 3, and others. Gaucher disease type 1 is the most common form and is characterized by a deficiency of the enzyme glucocerebrosidase. Diagnosis involves physical examinations, blood tests, imaging studies, preconception screening, prenatal testing, and other methods. Treatment options include enzyme replacement therapy and substrate reduction therapy, which can be administered via oral, parenteral, and other routes, and are provided by various end-users such as hospitals, specialty clinics, homecare services, and others.

The gaucher's disease market includes revenues earned by entities by providing services such as genetic counseling, patient education and support, research and clinical trials, and pain management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The gaucher's disease market consists of sales of bone health supplements, medical equipment, and diagnostic testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.